Literature DB >> 30362504

Itching, chloroquine, and malaria: a review of recent molecular and neuroscience advances and their contribution to mechanistic understanding and therapeutics of chronic non-histaminergic pruritus.

Adesuyi A L Ajayi1.   

Abstract

Chloroquine (CQ) is an antimalarial drug that elicits severe pruritus in black Africans with malaria fever. This acute itching (2-7 days duration) exhibits age dependency and a racial and genetic predilection. CQ itch is non-histaminergic, which makes it both a good model and a tool to probe the mechanisms of chronic itch. This review focuses on recently discovered mechanisms, neuroscience, mediators, and receptors that are implicated in molecular studies of CQ pruritus. CQ pruritus mechanisms are also compared to that of itching following other systemic diseases, such as chronic kidney disease, chronic liver disease, skin disorders, and burns. There are striking similarities between CQ itching pathways and other chronic itch secondary to systemic disease with or without skin lesions, which have not been previously highlighted. Prominent among these are the shared roles of skin, neural and spinal μ opiate receptors, kappa opiate receptor, nitric oxide, serotonin via 5HT1B/D receptors, cytokines, especially interleukins, and tumor necrosis factor. There is elaborate "cross talk" among the diverse mediators and receptors involved in CQ-induced pruritus. CQ also binds to the mas-related G protein coupled receptors MrgprA3/MrgprX1 present in a small proportion (4-5%) of dorsal root ganglion neurons and skin. The mrgprA3 CQ receptors are coupled to PLC-β3 and a chloride channel to initiate skin itch action potentials in C nerve fibers. Mrgpra3/X1 couples to TRPA1 for calcium influx into neuronal cells at noncutaneous sites. Central CQ itch occurs via gastrin-related peptide (GRP) and its receptor (GRPR) in the dorsal spinothalamic tracts, as well as glutamic mediated GRP projection to parabrachial nucleus. The possibility of chronic itch therapy based on personalized medicine, genetics, and transcriptomics or the use of itch "polypill/polycream" are discussed.
© 2018 The International Society of Dermatology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30362504     DOI: 10.1111/ijd.14252

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  7 in total

Review 1.  Pruritus in Autoimmune and Inflammatory Dermatoses.

Authors:  Claudia Zeidler; Manuel Pedro Pereira; Flavien Huet; Laurent Misery; Kerstin Steinbrink; Sonja Ständer
Journal:  Front Immunol       Date:  2019-06-21       Impact factor: 7.561

Review 2.  Systemic toxicity of chloroquine and hydroxychloroquine: prevalence, mechanisms, risk factors, prognostic and screening possibilities.

Authors:  Romain Muller
Journal:  Rheumatol Int       Date:  2021-04-24       Impact factor: 2.631

Review 3.  Autoimmune Connective Tissue Diseases-Related Pruritus: Proper Diagnosis and Possible Mechanisms.

Authors:  Lai-San Wong; Yu-Ta Yen
Journal:  Diagnostics (Basel)       Date:  2022-07-21

4.  Pruritus Associated with Commonly Prescribed Medications in a Tertiary Care Center.

Authors:  Amy H Huang; Benjamin H Kaffenberger; Adam Reich; Jacek C Szepietowski; Sonja Ständer; Shawn G Kwatra
Journal:  Medicines (Basel)       Date:  2019-08-04

Review 5.  Non-Analgesic Symptomatic or Disease-Modifying Potential of TRPA1.

Authors:  Stefan Heber; Michael J M Fischer
Journal:  Med Sci (Basel)       Date:  2019-09-23

Review 6.  Chloroquine and hydroxychloroquine in the treatment of malaria and repurposing in treating COVID-19.

Authors:  Zi-Ning Lei; Zhuo-Xun Wu; Shaowei Dong; Dong-Hua Yang; Litu Zhang; Zunfu Ke; Chang Zou; Zhe-Sheng Chen
Journal:  Pharmacol Ther       Date:  2020-09-08       Impact factor: 12.310

7.  Antipruritic Effect of Nalbuphine, a Kappa Opioid Receptor Agonist, in Mice: A Pan Antipruritic.

Authors:  Saadet Inan; Nae J Dun; Alan Cowan
Journal:  Molecules       Date:  2021-09-11       Impact factor: 4.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.